European Medicines Agency Recommends Additional Measures To Better Manage Risk Of Progressive Multifocal Leukoencephalopathy (PML) With Tysabri
Links shared publicly online about this topic.
- 1,438total visits
European Medicines Agency Recommends Additional Measures To Better Manage Risk Of Progressive Multifocal Leukoencephalopathy (PML) With Tysabri
The European Medicines Agency has finalised a review of Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. The A
View full resource at medicalnewstoday.com
Tags: Infection, Brain, Encephalitis, Tysabri
Most Recently Shared on January 22, 2010 at 12:37 pm By:
European Medicines Agency Recommends Additional Measures To Better Manage Risk Of Progressive Multifocal Leukoencepha.. http://bit.ly/5suA94
Advertisement
